---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-22-000461"
form_type: "8-K"
ticker: "IGC"
cik: "0001326205"
company_name: "IGC Pharma, Inc."
filed_at: "2022-04-18T23:59:59+00:00"
generated_at: "2026-06-26T06:49:06.562355+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# IGC obtains final court approval of shareholder class action settlement; lawsuits dismissed

## Summary
- Court granted final approval of settlement on April 13, 2022, dismissing Tchatchou and Harris-Carr consolidated class actions.
- Settlement resolves all shareholder class action lawsuits pending against IGC and its officers.
- Most settlement costs paid through company's insurance policy; terms previously disclosed in Form 10-Q filed Feb 10, 2022.
- IGC continues Alzheimer's drug development with IGC-AD1, a THC-based investigational drug; Phase 2 trial planned.

## SEC filing metadata
- accession: 0001185185-22-000461
- form_type: 8-K
- ticker: IGC
- cik: 0001326205
- company_name: IGC Pharma, Inc.
- filed_at: 2022-04-18T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326205/000118518522000461/0001185185-22-000461-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326205/000118518522000461/indiaglob20220418_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-22-000461
- JSON: https://secwatch.observer/filing/0001185185-22-000461.json
- Plain text: https://secwatch.observer/filing/0001185185-22-000461.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.